Physician profile
Robert Hieger
NPI 1801328612
$6,769.22
in general payments reported to CMS, 2019-2025
40 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $678 · 2022: $1,398 · 2023: $1,351 · 2024: $2,014 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,568.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,941.70 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $820.63 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $588.35 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $512.01 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $417.91 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $250.37 | 2023-2025 | Gemtesa |
| Amgen INC. | $192.21 | 2020-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $169.13 | 2021-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.98 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $151.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.46 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $124.71 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $122.22 | 2022-2024 | Veozah |
| Merck Sharp & Dohme LLC | $113.78 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $108.38 | 2021-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hieger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.